|Articles|August 8, 2014
The Value Discussion in Cancer Care Escalates: NICE and Roche
According to Sir Andrew Dillon, chief executive of NICE, the high price that Roche is demanding for Kadcyla is beyond the means of NHS to cover.
Advertisement
Sir Andrew Dillon, Nice chief executive says that the NHS cannot afford to pay Roche the high price it is demanding for its "miracle" breast cancer treatment. The drugs giant has responded by insisting that Nice is the only health body to conclude that Kadcyla is not good value for money.
Listen to the argument from both sides:
Source: The Telegraph
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show
2
COPERNICOS Trial: Eosinophil-Guided ICS Reduction Safe in COPD, Vestbo Says
3
FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations
4
Primary Care Capacity Gaps Threaten Respiratory Prevention
5